Suchen und Finden
Table of Contents
5
List of Contributors
11
Common Abbreviations
28
I Genomics and Proteomics
29
Rethinking Sepsis: New Insights from Gene Expression Profiling Studies
30
Introduction
30
How to Identify and Measure Heterogeneity
30
Sources of Heterogeneity in Sepsis Patients
31
New Insights from Gene-expression Studies
32
Genomic Heterogeneity
34
Further Questions on an Existing Sepsis Model
36
Functional Mapping of Sepsis Genome to Monitor Immune Function
37
Conclusion
39
References
39
Mitochondrial Genetics and Sepsis
41
Introduction
41
Oxidative Phosphorylation and ATP Generation
41
Reactive Oxygen Species
42
Apoptosis
42
Mitochondria and Sepsis
43
Mitochondrial Genetics
43
Mitochondrial Haplogroups
44
Conclusion
47
References
47
Lung Proteomics in Intensive Care
50
Introduction
50
The Search for Biomarkers
50
Lung Proteomics
52
Applications in ALI/ARDS
58
Future Directions
59
References
62
II Inflammatory Response
64
The Host Response to Sepsis
65
Introduction
65
Epidemiology and Genetic Variability
66
Pathogen Recognition Systems
67
Coagulation and Anticoagulation
70
Immune Suppression and Apoptosis
72
HMGB1 and RAGE
72
The Cholinergic Anti-inflammatory Pathway
73
Macrophage Migration Inhibitory Factor
74
C5a and C5a Receptor
74
Conclusion
74
References
74
Endotoxin Tolerance: Mechanisms and Clinical Applicability
77
Introduction
77
Mechanisms of Endotoxin Tolerance
77
Endothelial Function and Microcirculation during LPS Tolerance
79
Clinical Applicability and Therapeutic Possibilities
81
Conclusions
82
References
82
Oxidative Stress and Endothelial Dysfunction during Sepsis
85
Introduction
85
Sources and Actions of ROS and RNS in the Endothelium during Sepsis
85
Mechanisms of Endothelial Dysfunction during Sepsis
87
Conclusion
89
References
90
Measurement of Carbon Monoxide: From Bench to Bedside
91
Introduction
91
Carbon Monoxide Measurement
91
Carbon Monoxide Concentrations in Critically Ill Patients
92
Carbon Monoxide Concentrations and Lung Diseases
96
Carbon Monoxide Concentrations and Other Diseases
103
Conclusion
103
References
103
Monitoring Immune Dysfunction in Septic Patients: Toward Tailored Immunotherapy
107
Introduction
107
Monocyte Dysfunction
108
T Lymphocyte Dysfunction
111
Conclusion
114
References
115
III Current and Future Management of Sepsis
117
Source Control in the ICU
118
Introduction
118
What is ‘Source Control’?
118
Elements of Source Control
119
Do we need to perform Source Control?
120
When to Perform Source Control?
121
The Role of the Intensivist
121
What if Source Control is Impossible or Fails?
123
Special Considerations in Critically Ill Patients
123
Conclusion
125
References
125
IgM-enriched Immunoglobulins in Sepsis
127
Introduction
127
Mechanisms of Action of IVIG in Sepsis
128
Differences between IgG- and IgM-enriched Immunoglobulins
129
Clinical Significance of IgM-enriched IVIG
130
Conclusion
133
References
134
Clarithromycin: A Promising Immunomodulator in Sepsis
136
Introduction
136
Indirect Evidence for an Immunomodulatory effect of Macrolides in Pneumonia
137
Lessons from Animal Studies
138
Conclusion
141
References
142
High-flow Hemofiltration as an Adjunctive Therapy in Sepsis
144
Introduction
144
Mechanism of Action: Hemofiltration as a New Shield against the ‘Chaos Theory’ and ‘Complex Non-linear Systems’ in Sepsis
144
Recent Animal Trials and Clinical studies Highlighting the Crucial Roles of Dosing and Timing
146
Practical Aspects for the Bedside Clinician
148
Future Directions Regarding the Use of Hemofiltration in Sepsis
149
Conclusion
150
References
151
Economic and Social Burden of Severe Sepsis
154
Introduction
154
Concepts
154
Direct Costs of Sepsis Management
156
Direct Costs of Sepsis Management in Developing Countries: A Brazilian Experience
157
Indirect Costs and Burden of Illness
158
Impact of Therapeutic Strategies on Costs
159
Conclusion
161
References
162
IV Proposed Targets for New Therapies
164
Lymphocyte Apoptosis in Sepsis and Potential Anti-apoptotic Strategies
165
Introduction
165
Mechanisms of Apoptosis
166
Pathways Involved in Apoptosis
166
Evidence in Animals
168
Evidence in Humans
170
Therapeutic Molecular Targets
171
Conclusion and Perspectives
172
References
172
The Pivotal Role of Beta-adrenoreceptors in Critical Illness Pathophysiology
175
Introduction
175
New Concepts in Adrenoreceptor Signaling Biology
175
Desensitization of Beta-adrenoreceptors
177
Catecholamine-induced Immune Dysregulation
178
Beta-adrenoreceptor-mediated Metabolic Effects of Critical Illness
180
Beta-adrenoreceptor-mediated Effects on Barrier Gut Function
181
Specific Beta-adrenoreceptor-mediated Roles in Common Critical Illness Pathophysiology
181
Limitations of Current Experimental/clinical Data
182
Conclusion
182
References
183
Non-septic Acute Lung Injury and Inflammation: Role of TLR4
186
Introduction
186
Participation of TLR4 in Ischemia-reperfusion Injury
186
Heme Activates TLR4 by Different Mechanisms than does LPS
187
Acute Lung Injury Produced by Avian Influenza Virus H5N1 or Acid Aspiration is Dependent on Activation of TLR4 By Oxidized Phospholipids
189
Fragmented Hyaluronic Acid activates TLR4
189
TLR4 Participates in Inflammation Associated with Ventilator-induced Lung Injury or Cardiac Hypertrophy Produced by Aortic Stenosis
189
TLR4 Participates in Late Inflammatory Responses in which HMGB1 Plays a Contributory Role
190
Heat Shock Proteins (HSP) Induce Pro-inflammatory Cytokine Release through TLR4
190
TLR4 Participates in Ethanol-induced Inflammation
191
Acetaminophen-induced Liver Injury is TLR4-dependent
191
Conclusion
192
References
192
Hydrogen Sulfide: A Metabolic Modulator and a Protective Agent in Animal Models of Reperfusion Injury
195
Introduction
195
The Biological Chemistry of Hydrogen Sulfide
195
H2S as an Inducer of a State Resembling Suspended Animation
196
Protective Effects of H2S in Local or Whole-body Ischemia or Ischemia-reperfusion
198
Conclusion
200
References
200
V Septic Shock
204
‘Myocardial Depression’ or ‘Septic Cardiomyopathy’?
205
Introduction
205
Septic Cardiomyopathy: A Secondary Cardiomyopathy in the Scope of the Systemic Disease, ‘Sepsis’
205
How to Quantify Septic Cardiomyopathy?
208
Septic Cardiomyopathy is of Prognostic Relevance
209
Septic Cardiomyopathy: Triggers and Mechanisms
210
Causal Approaches towards the Treatment of Acute Septic Cardiomyopathy
213
Conclusion
214
References
214
Determinants of Tissue PCO2 in Shock and Sepsis: Relationship to the Microcirculation
217
Introduction
217
Mechanisms of Increase in Venous and Tissue PCO2: The Basics
217
Intramucosal Acidosis in Sepsis
223
References
225
Refining the Tools for Early Goal-directed Therapy in Septic Shock
227
Introduction: Initial Management of Septic Shock
227
Overview of Early Goal-directed Therapy
227
Therapeutic Steps and Goals and Proposed Refinements
230
Other Issues
236
Conclusion
237
References
238
VI Intravenous Fluids
241
Hyperchloremic Metabolic Acidosis: More than Just a Simple Dilutional Effect
242
Introduction
242
Mechanisms Underpinning pH Regulation: A Physico-chemical Approach
242
Effects of Plasma Volume Expansion on pH
244
Clinical Consequences of Hyperchloremic Metabolic Acidosis
245
Conclusion
251
References
251
Old versus New Starches: What do We Know about their Differences?
254
Introduction
254
Hydroxyethyl Starch Pharmacokinetics
254
Volume Effects
255
Renal Effects
257
Coagulation and Bleeding
257
Tissue Storage
259
Pruritus
259
Long-term Survival
260
Conclusion
260
References
261
Impact of Hydroxyethyl Starch on Renal Function
264
Introduction
264
Pharmacokinetic Profile of HES Solutions
264
Pathomechanisms of HES-induced Renal Dysfunction
266
Clinical Evidence of HES-induced Renal Dysfunction
268
Conclusion
271
References
272
Rational Approach to Fluid Therapy in Acute Diabetic Ketoacidosis
275
Introduction
275
Historical Perspective
275
Pathophysiology
276
Aims of Fluid Therapy
277
Optimal Management
278
Conclusion
282
References
282
VII Hemodynamic Support
284
Cardiac Filling Volumes and Pressures in Assessing Preload Responsiveness during Fluid Challenges
285
Introduction
285
Goals and Effects of Fluid Loading: Defining Preload and Fluid Responsiveness
285
Filling Pressures and Volumes of the Heart
286
Physiological Considerations and Clinical Implications
288
Conclusion
291
References
292
Update on Preload Indexes: More Volume than Pressure
295
Introduction
295
Filling Pressures (CVP and PAOP)
295
Continuous Right Ventricular End-diastolic Volume (cRVEDV)
297
Global-end Diastolic Volume and Intrathoracic Blood Volume
299
Conclusion
302
References
302
Monitoring Arterial Blood Pressure and Cardiac Output using Central or Peripheral Arterial Pressure Waveforms
305
Introduction
305
Wave Contour in the Central and Peripheral Arteries
306
Agreement between Central and Peripheral Blood Pressure in Specific Clinical Situations
308
Influence of the Site of Blood Pressure Measurement on Continuous Cardiac Output Estimation
309
Conclusion
314
References
314
Intrathoracic Pressure Regulation for the Treatment of Hypotension
317
Introduction
317
Active Intrathoracic Pressure Regulation Therapy for Apneic Hypotension Patients
317
Intrathoracic Pressure Regulation Therapy and CPR
319
Intrathoracic Pressure Regulation Therapy and Survival Outcomes in Hemorrhagic Shock
320
Intrathoracic Pressure Regulation Therapy and Sepsis
322
Potential Adverse Consequences and Limitations of Intrathoracic Pressure Regulation Therapy
323
Conclusion
323
References
324
Functional Hemodynamic Monitoring: A Personal Perspective
326
Introduction
326
Use of Dynamic Responses to Identify Nascent Cardiovascular States
327
Preload Responsiveness
327
Cardiovascular Sufficiency
328
Future Trends
329
References
330
VIII Airway Management
331
Endotracheal Intubation in the ICU
332
Introduction
332
Care Management Bundle to Increase the Safety of Endotracheal Intubation in the ICU
332
Conclusion
338
References
339
Pediatric Advanced Airway Management Training for Non-anesthesia Residents
341
Introduction
341
Risks associated with Tracheal Intubation and Provider Competence
341
Demand for Pediatric Airway Management Competence in Pediatric Resident Trainees
344
Process of Acquisition and Retention of Pediatric Tracheal Intubation Competence
345
Future Directions
348
Conclusion
348
References
349
Automatic Tube Compensation in the Weaning Process
351
Introduction
351
Automatic Tube Compensation
352
Commercially available Automatic Tube Compensation Systems
352
Potential Clinical Uses of Automatic Tube Compensation
353
Practical Aspects of using Automatic Tube Compensation
356
Conclusion
356
References
356
IX Mechanical Ventilation
358
Extracorporeal Membrane Oxygenation for Cardiac and Pulmonary Indications: Improving Patient Safety
359
Introduction
359
Application of ECMO Today
360
Further Development of ECMO
361
Control and Safety
363
References
366
Patient-ventilator Interaction during Non-invasive Ventilation
368
Introduction
368
NIV in Acute Respiratory Failure
368
Triggering of the Ventilator
369
Pressurization Slope
371
Level of Pressure Support
371
Cycling
372
Masks
373
Conclusion
374
References
374
Variable Mechanical Ventilation: Breaking the Monotony
377
Introduction
377
Patterns of Variability and their Characterization
377
Rationale for the Use of Variable Patterns in Mechanical Ventilation
379
History of Variable Mechanical Ventilation
379
Variable Controlled Mechanical Ventilation
380
Variable Assisted Mechanical Ventilation
381
Why does Respiratory Function Improve during Variable Mechanical Ventilation?
382
Is Variable Mechanical Ventilation Equivalent to Regular Ventilation with Intermittent Sighs?
384
Can Variable Mechanical Ventilation be Injurious?
385
Limitations of Variable Mechanical Ventilation
386
Conclusion
386
References
387
Life-threatening Asthma: Focus on Lung Protection
390
Introduction
390
Epidemiology
390
Definitions
391
Risk Factors
391
Pathophysiology of the Acute Asthma Attack
391
Therapeutic Approach
393
Conclusion
398
References
399
X Respiratory Monitoring
401
Bedside Monitoring of Diaphragm Electrical Activity during Mechanical Ventilation
402
Introduction and Background
402
Bedside Monitoring of EAdi
404
Conclusion
407
References
408
Electrical Impedance Tomography
411
Introduction
411
How Electrical Impedance Tomography Works
411
Clinical Applications
415
Potential Future Applications of Clinical Relevance
419
Conclusion
419
References
420
Regional Ventilation Delay Index: Detection of Tidal Recruitment using Electrical Impedance Tomography
422
Introduction
422
Individual PEEP Setting is Essential
422
Global and Regional Lung Function Parameters
423
Elecrical Impedance Tomography
423
The Concept of the Regional Ventilation Delay Index
424
Implementing Regional Ventilation Delay Index in Clinical Practice
425
Conclusion
428
References
428
Different Approaches to the Analysis of Volumetric Capnography
430
Introduction
430
Capnography: Types and Applications
430
Techniques for Volumetric Capnography Analysis
433
A New Algorithm for Volumetric Capnography Analysis
435
Conclusion
438
References
439
Variation in Extravascular Lung Water in ALI/ARDS Patients using Open Lung Strategy
441
Introduction
441
Measurement of EVLW at the Bedside
441
EVLW in ALI/ARDS Patients
444
Ventilation Strategy in ALI/ARDS and EVLW Variations
444
Conclusion
447
References
447
Clinical Utility of Extravascular Lung Water Measurements
450
Introduction
450
Measurement of EVLW
450
Limitations of the Measurement of EVLW by Transpulmonary Dilution Techniques
452
Clinical Utility of EVLW
455
Conclusion
457
References
457
XI Perioperative Management
460
Rationalizing the Use of Surgical Critical Care: The Role of Cardiopulmonary Exercise Testing
461
Introduction
461
Why Use Cardiopulmonary Exercise Testing as an Assessment Tool?
462
Which Patients should Undergo Cardiopulmonary Exercise Testing?
463
Cardiopulmonary Exercise Testing in Practice
464
Interpretation of Cardiopulmonary Exercise Test Data
466
Risk Stratification and Management using Cardiopulmonary Exercise Testing
468
Case Reports
469
Conclusion
475
References
475
Advanced Minimally Invasive Hemodynamic Monitoring of the High-risk Major Surgery Patient
477
Introduction
477
Definition and Role of Perioperative Optimization
477
Overview of Some Current Advanced Hemodynamic Monitors
479
Decline in Use of Central Venous Catheterization for Major Surgery
486
Conclusion
486
References
486
Post-pneumonectomy Pulmonary Edema
489
Introduction
489
Diagnostic Criteria
489
Prevalence
489
Pathology
490
Etiology
490
Conclusion
495
References
496
The Role of Phenylephrine in Perioperative Medicine
499
Role of the Calcium Sensitizer, Levosimendan, in Perioperative Intensive Care Medicine
514
Inhaled Nitric Oxide Therapy in Adult Cardiac Surgery
527
XII Cardiac Function
536
Use of Natriuretic Peptides in the Emergency Department and the ICU
537
Abnormalities of the ST Segment
545
Functional Mitral Regurgitation in the Critically Ill
557
XIII Cardiopulmonary Resuscitation
566
Feedback to Improve the Quality of CPR
567
The Post-cardiac Arrest Syndrome
577
Use of a Standardized Treatment Protocol for Post-cardiac Resuscitation Care
587
Therapeutic Hypothermia after Cardiac Arrest
601
XIV Renal Function
612
Biomarkers of Acute Kidney Injury in Critical Illness
613
The Role of Biomarkers in Cardiac Surgeryassociated Acute Kidney Injury
622
Neutrophil Gelatinase-associated Lipocalin: An Emerging Biomarker for Angina Renalis
630
XV Hepatosplanchnic Function
637
How does Intra-abdominal Pressure Affect the Daily Management of My Patients?
638
ICG Clearance Monitoring in ICU Patients
655
Acute-on-Chronic Liver Failure in Cirrhosis: Defining and Managing Organ Dysfunction
667
XVI Nutrition
681
The Curse of Overfeeding and the Blight of Underfeeding
682
Enteral Feeding during Circulatory Failure: Myths and Reality
690
Enteral Nutrition with Anti-inflammatory Lipids in ALI/ARDS
702
Glutamine Supplementation in ICU Patients
712
XVII Glucose Control
723
Burn Causes Prolonged Insulin Resistance and Hyperglycemia
724
Glucose Variability in Critically Ill Patients
733
XVIII Adrenal Function
743
Corticosteroid Biology in Critical Illness: Modulatory Mechanisms and Clinical Implications
744
Corticosteroid Treatment of Patients in Septic Shock
756
XIX Coagulation
764
New Anticoagulants: Anti-IIa or Anti-Xa Agents?
765
Emergency Reversal of Anticoagulants
771
XX Neurological Aspects
782
The Role of Imaging in Acute Brain Injury
783
Monitoring and Managing Raised Intracranial Pressure after Traumatic Brain Injury
801
Sepsis-associated Encephalopathy
809
XXI Malignancies
817
Acute Tumor Lysis Syndrome: Diagnosis and Management
818
Life-threatening Neurological Complications in Patients with Malignancies
827
Should We Admit Critically Ill Cancer Patients to the ICU?
844
XXII Drug Dosing
855
Optimizing Drug Dosing in the ICU
856
Relevant CYP450-mediated Drug Interactions in the ICU
867
XXIII Sedation and Analgesia
875
Sedation and Pain Management in the ICU
876
The Role of Dexmedetomidine in Intensive Care
901
Monitoring Delirium in the ICU
910
XXIV ICU Management
927
Intensive Care for the Elderly: Current and Future Concerns
928
ICU Performance: Managing with Balanced Scorecards
937
XXV End-of-Life Issues
951
Managing Conflict at the End-of-Life
960
Strengths and Weaknesses of Substitute Decision Making in the ICU
970
Subject Index
980
Alle Preise verstehen sich inklusive der gesetzlichen MwSt.